Colossal Biosciences at a glance
As of- [1] Latest valuation: Colossal Biosciences, September 18, 2025
- [2] Total funding (reported): Colossal Biosciences, September 18, 2025
- [3] Founded: Wikipedia (retrieved September 5, 2026)
- [4] Headquarters: Wikipedia (retrieved September 5, 2026)
Ranked on: #2 Top Health & Biotech Startups 2026 · #45 Most Valuable Private Companies 2026 · Get your badge →
Is this your company? Get featured or correct your listing →
Company Snapshot
Colossal Biosciences is a Biotech company, based in Dallas, Texas, USA, founded 2021 by George Church, Ben Lamm.
Recent changes
- Jul 20, 2026Jul 20, 2026Colossal Biosciences in Talks to Raise at $20B-$30B Valuation Pulse story
- Jul 20, 2026Jul 20, 2026Colossal Biosciences in Talks to Raise at Up to $30B Valuation Pulse story
- Sep 18, 2025Sep 18, 2025Raised $120M Series C (extension) Colossal Biosciences
- Sep 18, 2025Sep 18, 2025Valuation rose from $10.2B to $10.32B Colossal Biosciences
- Jan 2025Jan 2025Raised $200M Series C at a $10.2B valuation Wikipedia
Funding history
3 equity events · newest first · sources dated per row| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Sep 18, 2025 | Series C (extension) | $120M | — | — WithUSIT | Colossal Biosciences |
| Jan 2025 | Series C | $200M | $10.2Bpost-money | — | Wikipedia |
| Funding roundRumorednot counted: rumored | — | $20B–$30Bpost-money | — | TechCrunchPulse story |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
Investors
Latest Pulse
- Oct 22, 2026Warhound Raises $200M To Build Military Working DogsBen Lamm's new venture raised $200 million from Sequoia, 8VC and the CIA-backed In-Q-Tel to genetically engineer dogs for the military -- before a single dog exists.→
- Oct 17, 2026NeoGenesis Capital Launches To Back Colossal BiosciencesXPRIZE founder Peter Diamandis and biologist Yianni Psaltis closed the first fund of NeoGenesis Capital, a venture firm built to back Colossal Biosciences and startups spun from its programmable-biology platform.→
- Oct 14, 2026Colossal's New AI Platform Maps A Path Back To The DodoColossal Biosciences unveiled GenoMorph, an AI platform combining genomics and developmental biology that has already flagged about 2,300 candidate gene edits for reviving the dodo's skull shape.→
- Aug 20, 2026Colossal Spinout Astromech Hits $3.8B on Biology AIAstromech, a Colossal Biosciences spinout co-founded by Ben Lamm and George Church, raised $20M at a $3.8B valuation to build AI models that predict evolutionary biological change.→
- Jul 21, 2026Dimension Capital Raises $800M Fund for Science-Meets-Compute BetsDimension Capital closed an $800 million third fund aimed at the intersection of scientific research and compute infrastructure, underscoring how much venture capital is now chasing the compute-heavy science boom.→
- Jul 21, 2026AI Cracks Century-Old Jacobian Conjecture, Stunning MathematiciansAn AI system helped resolve the century-old Jacobian conjecture, according to Fortune, with mathematicians describing the pace of AI progress on unsolved problems as unsettling rather than purely celebratory.→
- Jul 20, 2026Colossal Biosciences in Talks to Raise at Up to $30B ValuationColossal Biosciences is reportedly in talks to raise new capital at a $20-30 billion valuation, up to triple its January 2025 mark, building revenue-generating spinouts beyond its mammoth and dire wolf projects.→
- Jul 20, 2026Colossal Biosciences in Talks to Raise at $20B-$30B ValuationDe-extinction genetics company Colossal Biosciences is reportedly in talks to raise new capital at a $20 billion to $30 billion valuation, a dramatic step up that would make it one of the most valuable biotech startups in the world.→
Coverage Timeline
newest first- Oct 17, 2026PEOPLENeoGenesis Capital Launches To Back Colossal Biosciences→
- Oct 14, 2026AIColossal's New AI Platform Maps A Path Back To The Dodo→
- Aug 20, 2026FUNDINGColossal Spinout Astromech Hits $3.8B on Biology AI$20M at $3.8B→
- Jul 20, 2026FUNDINGColossal Biosciences in Talks to Raise at Up to $30B Valuation$20B-$30B talks→
- Jul 20, 2026FUNDINGColossal Biosciences in Talks to Raise at $20B-$30B Valuation$20B-$30B valuation→
All Coverage
PEOPLE
NeoGenesis Capital Launches To Back Colossal Biosciences
XPRIZE founder Peter Diamandis and biologist Yianni Psaltis closed the first fund of NeoGenesis Capital, a venture firm built to back Colossal Biosciences and startups spun from its programmable-biology platform.
DEEP DIVE
Colossal's New AI Platform Maps A Path Back To The Dodo
AI
Colossal's New AI Platform Maps A Path Back To The Dodo
Colossal Biosciences unveiled GenoMorph, an AI platform combining genomics and developmental biology that has already flagged about 2,300 candidate gene edits for reviving the dodo's skull shape.
DEEP DIVE
Colossal Spinout Astromech Hits $3.8B on Biology AI
FUNDING$20M at $3.8B
Colossal Spinout Astromech Hits $3.8B on Biology AI
Astromech, a Colossal Biosciences spinout co-founded by Ben Lamm and George Church, raised $20M at a $3.8B valuation to build AI models that predict evolutionary biological change.
DEEP DIVE
Colossal Biosciences in Talks to Raise at Up to $30B Valuation
FUNDING$20B-$30B talks
Colossal Biosciences in Talks to Raise at Up to $30B Valuation
Colossal Biosciences is reportedly in talks to raise new capital at a $20-30 billion valuation, up to triple its January 2025 mark, building revenue-generating spinouts beyond its mammoth and dire wolf projects.
Colossal Biosciences in Talks to Raise at $20B-$30B Valuation
FUNDING$20B-$30B valuation
Colossal Biosciences in Talks to Raise at $20B-$30B Valuation
De-extinction genetics company Colossal Biosciences is reportedly in talks to raise new capital at a $20 billion to $30 billion valuation, a dramatic step up that would make it one of the most valuable biotech startups in the world.
Value Add Research
Related Companies
Shared investors
Colossal Biosciences FAQ
What is Colossal Biosciences's valuation?
Colossal Biosciences was last valued at $10.32B, according to Colossal Biosciences (September 18, 2025).
How much has Colossal Biosciences raised?
Colossal Biosciences has raised $555M+ in total funding, according to Colossal Biosciences (September 18, 2025).
When was Colossal Biosciences founded and where is it based?
Colossal Biosciences was founded in 2021 and is headquartered in Dallas, Texas, USA, according to Wikipedia.
Sources & methodologyshow
Where these figures come from
- TechCrunchmajor outlet1 fact
- Colossal Biosciencesresearch database3 facts
- WikipediaValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.